Developments of mucus penetrating nanoparticles  by Liu, Min et al.
w.sciencedirect.com
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 7 5e2 8 2HOSTED BY Available online at wwScienceDirect
journal homepage: ht tp: / /ees.e lsevier .com/ajps/defaul t .aspReviewDevelopments of mucus penetrating nanoparticlesMin Liu, Jian Zhang, Wei Shan, Yuan Huang*
Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy,
Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, Chinaa r t i c l e i n f o
Article history:
Received 6 December 2014
Accepted 31 December 2014





Experimental strategies* Corresponding author. West China School of
E-mail address: huangyuan0@163.com (Y. H
Peer review under responsibility of Shenyan
http://dx.doi.org/10.1016/j.ajps.2014.12.007
1818-0876/© 2015 Shenyang Pharmaceutical
CC BY-NC-ND license (http://creativecommoa b s t r a c t
Mucus can effectively protect the exposed mucosal surfaces due to its adhesive and
viscoelastic properties. Most foreign particulates are efficiently trapped in mucus layers via
steric obstruction and adhesion. Trapped particles are typically removed from the mucosal
tissue within seconds to a few hours depending on their location sites. This article focuses
on describing the tenacious mucus barrier properties, the strategies to investigate the
interaction of nanoparticles with the mucus as well as the novel developments of mucus
penetrating nanoparticles.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Nanocarriers have emerged as an effective strategy for mu-
cosa delivery of drugs, which possess a series of desirable
properties, including small steric obstruction due to their
nanometer size, and protection of cargo therapeutics at both
the extracellular and intracellular levels [1]. However, one of
the greatest challenges that limit the success of nanoparticles
(NPs) is their ability to penetrate quickly through mucus to
reach the underlying cells.
Mucus is a viscoelastic and adhesive hydrogel that covers in
the surface of lung airways, gastrointestinal (GI) tract, female
reproductive tracts, eye and other mucosa [2]. Mucus protects
underlying epithelium by efficiently trapping pathogens and
foreign particulates, then rapidly removing them. Therefore,
mucus is not only vital for human health, but also represents a
substantial barrier to mucosal drug delivery. Mucus forms ad-




ns.org/licenses/by-nc-ndinteractions, van der Waals forces, hydrophobic forces,
hydrogen bonding, and chain entanglement [3,4]. Mucoadhe-
sive NPs is to prolong the retention time of particles inmucosal
surface by maximize these interactions [5], which would un-
dergo either direct transit or elimination. Different mucoad-
hesive systems have been well reviewed previously [6,7].
Another strategy to overcome the mucus barrier and ach-
ieve longer retention time in cell surface is to develop a
nanocarrier which can effectively penetrate the mucus layer
and accumulate in epithelial surface. Justin Hanes and co-
workers first proposed mucus penetrating particles (MPP) by
mimicking the essential surface properties of viruses that
allow them to avoidmucoadhesion [5], showing great promise
in mucosal drug delivery. Thereby, the aim of present study is
to summarize the properties of mucus, approaches for
designing NPs to conquer the mucus barrier as well as the
strategies used to investigate the interactions betweenmucus
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Mucus is a viscoelastic, adhesive gel that coats and protects
most epithelial surfaces, which efficiently trap most foreign
particles and pathogens through adhesive and steric in-
teractions, followed by rapid clearance. Fig. 1 illustrated the
fate of foreign particulates, including penetrating through
mucus (A), trapping in mucus (B) and excluding by mucus (C)
[8]. The following will elaborate the reasons resulting in
various fates of foreign particulates.
2.1. Composition of mucus
Mucus is a hydrogel complex composed of carbohydrates,
protein, lipids, antibody, cellular debris bacteria and inorganic
salts [9]. The barrier properties of mucus are rooted in its
dense network of mucin fibers, which contain highly glyco-
sylated (negatively charged) segments [5], thus show high af-
finity with positively charged particles. For example, Laffleur F
et al. reported that the diffusion rate of neutral polyacrylic
acid (PAA)-polypropylene amide (PAM) nanoparticles (NPs) is
2.5-fold higher than positively charged PAM NPs [8]. Similar
phenomenon also has been reported by other groups that NPs
with positively charged surface can be trapped in mucus
effectively own to strong electrostatic interactions [10].
Additionally, there exist periodic hydrophobic domains
along the mucin strains [11], which can bind hydrophobic
particles with high avidity. Although hydrophobic interactions
effectively limit the transport of some harmful agents such as
bacteria [12,13], it also represents a challenge for the delivery of
drug carriers, since the commonly used biomaterials are hy-
drophobic, like poly (lactic-co-glycolic acid) (PLGA) [14,15] and
polystyrene (PS) [16]. However, after coating PLGA NPs with
hydrophilic DNA, the average transport rates can be improved
10-fold in reconstituted pig gastric mucus [17].
2.2. Viscoelasticity
The viscoelasticity of mucus are essential for its protective
properties. As reported, a rather moderate decrease ofFig. 1 e Summary the fate of foreign particulates: (A) mucus
penetrating particles, (B) mucus adhesive particles and (C)
mucus excluding particles. Figure obtained from Ref. [8].viscoelasticity can significantly promote bacterial and
sperm motility [11]. Mucin, as the main component of
mucus, directly affects the viscoelastic properties of mucus.
A series studies have shown that the mucins can be
changed in amount, type and size in disease [18e20]. For
instance, compared with healthy secretions, the mucin
concentration increased approximately 7-fold for patient
with asthma, further increasing the difficulty of mucosal
drug delivery [21]. Apart from mucin, other factors also play
a key role in regulating mucus viscoelasticity, including
lipids, inorganic salts, pH and cellular debris. The cell debris
DNA can further increase the viscoelasticity of mucus due to
its fibers are even longer than mucin fibers [18]. Besides,
highly acidic environments (pH < 4) would cause the ag-
gregation of mucin fibers and greatly increase the mucus
viscoelasticity [22]. Therefore, to ensure free diffusion of
NPs in mucus, large amounts of mucus mucolytic agents
can be adopted to reduce the viscoelasticity of mucus
(Fig. 2), including papain [23,24], recombinant human DNase
(rhDNase) [10,25], N-acetyl-L-cysteine (NAC) [26] and gulur-
onate oligomers [27].2.3. Steric obstruction
Mucus gel is composed of highly cross-linked mucin fibers
by hydrophobic interactions and disulfides link, creating a
dense porous structure. However, mucus displays different
pore size depending on its location on the body, such as, the
average pore size of human cervicovaginal mucus (CVM) is
340 ± 70 nm [28] and 550 ± 50 nm for fresh bovine vitreous
[29], while smaller mesh spacing inherent to cystic fibrosis
(CF) sputum (140 ± 50 nm) own to the higher concentrations
of mucins, DNA, and actin [30]. Thereby, to penetrate
mucus, nanocarriers must be small enough to avoid
steric obstruction in spite of NPs with larger size are
preferred to improve drug loading and release kinetics [5].
As reported, a 2-fold increase in particle size, from 510 nm
to 1190 nm for PS-PEG NP, would led to a 30-fold decrease
in the ensemble-averaged mean squared displacement [29].
It also has been reported that the nanospheres size
approaching 560 nm were almost completely blocked by
the sputum [25]. Similarly, Norris and Sinko studied the
diffusion of variously sized PS particles in reconstituted
porcine gastric mucin gel, and observed a sharp decrease in
translocation permeability when particle sizes reach
300 nm [31].2.4. Dynamic properties
Mucus is constantly secreted, subsequently shed and dis-
carded or digested and recycled. Its turnover time is short,
especially for the loosely adherent mucus layer, often
measured in minutes to hours. For oral drug delivery, the in-
testinal mucus turnover time is 50e270 min [32], resulting in
efficient clearance of administered particulates.
In conclusion, the understanding of mucus compositions
and properties is important to design nanocarriers which can
avoid the blockage inmucus,meanwhile penetratemucus at a
rate significantly higher than mucus turnover cycle.
Fig. 2 e Scanning electron microscopy of purified pig gastric mucin, (A) without and (B) with mucolytic agents.
Figure obtained from Ref. [27].
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physicochemical properties
NPs properties including charge and hydrophobicity have a
great influence on their behavior of penetrating through
mucus. As a consequence, to prepare NPs with a sufficiently
hydrophilic and uncharged surface to effectively minimize
the adhesive interactions betweenmucin and NPs by reducing
hydrophobic or electrostatic interactions, show promise
prospect on mucus penetrating.3.1. PEG-modified NPs
Coating NPs with low molecular weight (MW) PEG is the most
widely studiedmucus penetrating strategy (Fig. 3A) [33]. There
are various PEG modified MPP described in the literature
(Table 1). PEG is an uncharged hydrophilic polymer whichwas
used to increase the mucus adhesion in earlier studies [34,35].
While later researches have shown that coating NPs with a
high density of low MW PEG can reduce the interactions be-
tween particle and mucus. The possible reasons are as fol-
lowings: the MW of PEG was too low to support adhesion via
polymer chains interpenetration and the PEG density is suf-
ficient to shield the hydrophobic core effectively [36]. ToFig. 3 e Schematic diagram of MPP, (A) PEG-modified NPs, (B) Pl
barrier by mucolytic agents. Figure obtained from Refs. [33,45,2determine the effect of PEG MW on the interactions of coated
particles withmucus, Hanes et al. studied the diffusion rate of
PS NPs modified by different MW (2, 5 and 10 kDa) and den-
sities (42 ± 3%, 65 ± 1% and 69 ± 1%) of PEG in CVM. The
experimental results showed that low MW (e.g. 2 kDa) and
high-density (e.g. 65e70%) PEG coating can facilitate the NPs
to pass through mucus [36]. Apart from modified PS NPs, PEG
also can be used to conjugate with other polymeric materials
to prepare MPP, like PLGA [37], poly sebacic acid (PSA) [38],
polyethylenimine (PEI) [39] and poly-L-lysine (PLL) [40].
Furthermore, densely PEGylated particles are able to readily
penetrate chronic rhinosinusitis mucus (CRSM) samples and
sputum expectorated from the cystic fibrosis (CF) patients
with higher viscosity [37].
In addition to covalent conjugation of PEG to the particles
core, PEG also can be physically absorbing on the particle
surface by hydrophobic or electrostatic interactions [41,42].
This kind of NPs has similar mucus penetrating properties as
long as their surface is densely coated by low MW PEG.
3.2. Pluronic F-127 modified NPs
Triblock copolymer of poly (ethylene glycol)-poly (propylene
oxide)-poly (ethylene glycol) (PEG-PPO-PEG; known as Plur-
onics) has a long application history in oral, intravenous anduronic F-127 modified NPs and (C) disrupting the mucus
3].
Table 1 e Various PEG modified MPP described in the literature.
Core Drug Mucus model
Covalent conjugation PS DNA Bovine vitreous
PS Doxorubicin CVM
PS e Respiratory mucus from humans without lung diseases
PSA e CVM and CF sputum
PLGA e CRSM
PAMAM e CF sputum
PLL DNA CF sputum
PEI DNA CF sputum
Physical absorption
PEG-Vitamin E PLGA Doxorubicin CVM
PEG-APCs Recombined adenoviral Vaccines CVM
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particle surfaces by adsorption of the hydrophobic PPO seg-
ments, leaving a dense brush of uncharged, hydrophilic PEG
segments protruding from the particle surface [43] (Fig. 3B).
Studies have shown that Pluronics containing PPO segments
with MW > 3 kDa, such as F-127, can produce MPP. Coating
PLGA nanoparticles with Pluronic F127 can effectively block
adhesive interactions between the PLGA core and mucus
constituents, which are similar to covalent conjugation of PEG
to PLGA, simultaneouslywithout changing the structure of the
PLGA carrier materials [44]. Other studies also indicated that
the average speed for PLGA/F127 particles was only 20-fold
reduced compared to their theoretical speed in water (un-
coated PLGA particles were slowed by>1000-fold) [37]. Simi-
larly, X. Li et al. designed a core shell corona nanolipoparticles
(CSC) which contains chitosan NPs as a core component and
pluronic F127-lipid vesicles as a shell with hydrophilic chain
and polyethylene oxide PEO as a corona for oral protein de-
livery. CSC can further improve the absorption of drug
through enhanced intestinal mucus penetration [45]. Addi-
tionally, other study compared the mucus penetrating
behavior of Pluronic F127-modified liposomes (PF127-Lip) and
chitosan-modified liposomes (CS-Lip). Pharmacokinetic anal-
ysis in rats shows that the Cmax and AUC0et of F127-Lip were
1.73-fold and 1.84-fold higher than those of CS-Lip, respec-
tively. This indicated F127-Lip more suitable for drug nano-
carriers [46]. Besides, it is interesting to found that PS NPs can
rapidly penetrate CVM if the CVM is pretreated with sufficient
concentrations of F127 [47].
However, it needs to be noticing that not all hydrophilic
and neutral modification can facilitate mucus penetration.
Like hydrophilic and uncharged polyvinyl alcohol coated PS
NPs were immobilized, with speeds at least 4000-fold lower in
mucus than in water, regardless of the MW or incubation
concentration of PVA [48].4. MPP by disrupting the mucus barrier
Due to the tenacious and sticky network of mucin fibers, the
diffusion of foreign particles is restricted by trapping and steric
hindrance. According to the nature of mucus, a technique to
reach the underlying cell layer is presented by disrupting the
mucoglycoprotein substructures using mucolytic agents [49]
(Fig. 3C). For example, Mu¨ller C and coworkers prepared NPs
composed of polyacrylic acid (PAA) and papain. The presenceof papain on the surface and inside of the particles could
strongly decrease viscosity of the mucus thus leading to par-
ticle transition across the mucus layer quickly [23,24].
In addition, recombinant human DNase (rhDNase) is the
most commonly used mucolytic in CF, which can hydrolyzes
the DNA that forms dense entanglements with mucin glyco-
proteins and other mucus constituents, thus reducing the
number of viscoelasticity and crosslinks of mucus [50].
Sanders et al. observed rhDNase moderately facilitated the
transport of nanospheres through CF sputum [25]. However,
Dawson et al. found that treatment with rhDNase dramati-
cally narrowed the distribution of individual particle diffusion
rates and reduced macroviscoelastic properties of CF sputum
by up to 50%, but did not significantly alter the ensemble-
average particle diffusion rate. This might attribute to the
hydrolytic cleavage of DNA into smaller fragments which
diffuse freely into micropores and then increased the micro-
viscosity within the pores [10].
N-acetyl-L-cysteine (NAC) is another common mucolytic
for its ability to facilitate the penetration of NPs across CF
sputum. NAC disrupts the structure of the mucus polymer by
substituting free thiol (sulfhydryl) groups for the disulfide
bonds connecting with mucin proteins [26]. As a result, both
the elasticity and viscosity of the mucus are lowered. Alton
et al. found that the mucus barrier to non-viral gene vectors
can be overcome partially by treatment with NAC in an ex vivo
model of sheep tracheal epithelium [51]. However, it is still
need further investigation to clarify if the combination of
polymeric NPs with mucolytic agents will promote more en-
dotoxins and other toxic substances absorption by decreasing
the local viscosity of mucus layer.5. Research strategies of mucus penetration
5.1. Diffusion experiments
Methods used to study particle diffusion in mucus include
multiple particle tracking (MPT), Ussing chamber or Trans-
welleSnapwell diffusion chamber and so on. Trans-
welleSnapwell diffusion chamber was first used for
quantitatively measuring the diffusivity of particles in mucus,
which consists of two chambers with the placement of the
mucus layer in the middle. Although this method is concep-
tually straightforward, it is also sensitive to parameters that
are difficult to control, including the thickness of the mucus
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 7 5e2 8 2 279sample, alterations in mucus properties and blockage of filter
pores by mucus [52].
In order to avoid the defects in diffusion chamber experi-
ments, many studies recorded the NPs dynamic transit in the
mucus using fluorescence microscopy, such as fluorescence
recovery after photobleaching (FRAP) and multiple particle
tracking (MPT). FRAP is the fluorescently labeled NPs exposure
to a laser beam to form a floating white spot. The diffusion
coefficient is obtained by the recovery of the fluorescence in-
tensity, which results following diffusion of the fluorescently
labeled molecules into this area with the flow of NPs [53]. Shen
et al. applied FRAP to examine the diffusion of plasmid DNAs in
mucus [54]. Additionally, FRAP also has been used to investi-
gate the effect of guluronate oligomers on mobility of NPs in
mucous matrices, and results showed that guluronate oligo-
mers can improve NPs mobility in native pig gastric mucus
(Fig. 4A and B) [27]. FRAP can be used to investigate themobility
of labeled molecules in mucus and biogels, but it provides only
ensemble-averaged diffusion rates and cannot be used to
quantify the transport rates of individual particles. A lack of
information at the individual particle level may limit its
application in complex mucus [55]. For this purpose, Hanes
et al. have pioneered MPT to measure the transport of NPs in
mucus. As shown in Fig. 4C and D [56], it can record each
particle trajectories by inverted fluorescence microscope
meanwhile MPT can be used for analysis of NPs in some
complex biological fluids, such as sputum [57]. Apart from this,
the diffusion behavior of NPs in the mucus also can be studied
by rotating diffusion tubes [58] and mucus slices [59] etc.Fig. 4 e (A) and (B) FRAP curves for NPs in native pig gastric mucu
from Refs. [27,56].5.2. Cell models
5.2.1. HT29-MTX cell model
HT29 cells belong to human colonic adenocarcinoma cell line.
Under the influence of methotrexate (MTX) [60], HT29 differen-
tiated into mature goblet cells, such as E12 cells, which can
secrete mucus. Therefore, HT29-MTX cells can be used to study
the influenceofmucus layeronNPs transport [61].However, this
modelhassomedrawbackscompared to the invivosituationdue
to it is based on only one cell type of the intestinal epithelium.
5.2.2. Caco-2/HT29-MTX co-cultures cell model
Human colon carcinoma Caco-2 and HT29 cells were estab-
lished to represent the two most abundant cell populations in
the intestinal epithelium, absorptive cells and goblet cells.
Therefore, co-cultures of Caco-2 cells and mucus-producing
goblet cells HT29-MTX would provide a drug absorption
model incorporating the mucus barrier [62]. Wilkman-Larhead
first characterized co-cultures of Caco-2 and goblet-like HT29-
MTX cells as in vitro drug and peptide absorption models [63].
In general, a higher amount of Caco-2 cells leads to higher
transepithelial electrical resistance (TEER) values probably due
tomore intensely formed tight junctions. When HT29 cell ratio
is 25%, the change of TEER value is 0e790 Ucm2 in 0e23 days.
when the ratio is 75%, the TEER value downgrade to
0e310 Ucm2. Goblet cells comprise a quantitatively significant
component of the GI tract, comprising approximately 10% of
the duodenal epithelium and increasing to 24% in the distal
colon. Thus, to maintain better in vivo/in vitro correlations, (C) and (D) particle tracking experiments. Figure obtained
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 7 5e2 8 2280relevance, the co-cultures proportion of Caco-2/HT29-MTX is
90%/10% or 75%/25% mostly [64,65].
5.2.3. Caco-2/HT29-MTX/Raji B triple culture model
Apart from enterocytes and goblet cells, M cells located in the
epithelium that overlay the Peyer's patches also play a domi-
nant role. Several reports suggest that NPs are capable to enter
intestinal epithelia via M cells while uptake by absorptive
enterocytes only plays aminor role [66,67]. In order to design a
model which can mimic the small intestinal epithelial more
accurately, some studies establish an in vitro cellular model
based on Caco-2, mucus-producing HT29-MTX, and human
Burkitt's lymphoma Raji B cells which represent M cells. The
model was set up by seeding co-cultures of Caco-2 and HT29
cells into Transwell filters and maintained under identical
conditions following the addition of Raji B to the basolateral
chamber [68,69].
In addition, there were also studies designed and charac-
terized biosimilar mucus compatible with Caco-2 cell mono-
layers cultured in vitro to establish a more representative
in vitro model for the intestinal mucosa to predict the influ-
ence of mucus on intestinal drug absorption [70].
5.3. Animal models
To better understand the fate of the particles and how the
results might translate in humans, many studies adopt ani-
mal models to investigate the therapeutic effects or pharma-
cokinetics of NPs, which mainly include isolated intestinal
experiments, in situ experiments and in vivo experiments.
5.3.1. Isolated intestinal model
To avoid the shortcomings of cell monolayer model such as
lack of three-dimensional macrostructure and cells of varying
degrees of differentiation, some studies adopted isolated in-
testinal experiments (including everted intestinal sac and
permeability study by Ussing chamber [71]) to measure the
mucoadhesive properties of NPs. However, in suchmodel, the
intestinal need to be removed, opened, washed and
segmented, which may change the intestinal property and
failed to predict what occurred in vivo [72].
5.3.2. In situ model
Intestinal loop models have been used for decades to inves-
tigate systemic absorption of drugs. In this model, a portion of
the small intestine is excised from the abdominal cavity,
subsequently ligated at both ends to make an isolated “loop”,
and the test NPs is directly injected into the loop. After a
chosen time period, the animal is sacrificed and the intestinal
loop is removed from the body cavity for further morphology
or quantitative analysis [73]. Several studies have used this
model to investigate the influence ofmucus onNPs absorption
and the amounts of NPs trapped in mucus [45,46].
5.3.3. In vivo model
No matter how sophisticated an in vitro model, eventually
in vivo evaluation is necessary to validate the true perfor-
mance of a drug delivery system. For example，the significant
difference existed in mucus composition and thickness with
the position of the GI tract, it is difficult to simulate thesein vitro experiments. However, a shortcoming existed in all
models so far is their non-human nature, which shows great
difference in human studies [72].6. Conclusions
Mucus layer covering in exposed epithelial surfaces of the
body has vital protective and lubrication effect. However, the
adhesive and rapidly update properties of mucus is one of the
main barriers for mucosal drug delivery. A promising strategy
to tackle this problem is use ofMPPwhich can readily infiltrate
into the mucus layer before turnover occurring. While some
problems for MPP including the epithelial barrier, the security
of MPP and suitable mucus models still need to be further
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